CA-BELKIN
7.6.2022 18:02:05 CEST | Business Wire | Press release
Belkin , a global consumer electronics leader, today announces three new additions to its growing SOUNDFORM audio portfolio – the SOUNDFORM Immerse Noise Cancelling Earbuds, the SOUNDFORM Play True Wireless Earbuds, and SOUNDFORM Nano Wireless Earbuds for Kids. The new SOUNDFORM solutions fill out Belkin’s vast true wireless audio collection, offering wireless earbuds for wide age ranges and at various price points.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220607005084/en/
“Since launching the Belkin SOUNDFORM™ audio line just a few years ago, we introduced a variety of innovative audio solutions ranging from award-winning premium smart speakers to popular kids' headphones,” says Melody Tecson, senior director of product management, Belkin. “Our audio team has deep expertise in the acoustic industry and delivers high quality true wireless earbud solutions that will complement day-to-day activities from working out, taking work calls, or studying at home.”
SOUNDFORM™ Immerse Noise Cancelling Earbuds
Announced earlier this year at CES 2022, the SOUNDFORM Immerse Noise Cancelling Earbuds are Belkin’s top-of-the-line audio solution designed for true audiophiles who value a feature-rich solution and premium listening experience.
Key features:
- Hybrid ANC (Active Noise Cancellation) and 3 microphones per earbud filter and eliminate unwanted noise for clearer call quality and an ideal listening experience
- Hear-Thru mode enables users to adjust ambient sound levels so they can stay alert of their surroundings
- Multipoint connection offers seamless switching between multiple devices
- 12mm dual-layer dynamic drivers with neodymium magnets and aptX audio technology offer intensely vivid sounds and truly immersive audio moments
- 31 hours of battery life – 7 hours of playtime per charge for the earbuds, plus another 24 hours of battery in the wireless charging case for uninterrupted talking, listening, and streaming
- Locating capabilities with Apple Find My network to locate charging case, and Belkin Ping My Earbuds feature to locate earbuds
- Google Fast Pair allows Android phones to instantly connect with a simple tap
- Accompanying SOUNDFORM app provides advanced customization features such as personalized EQ settings and adjustable Hear-Thru levels
- Qi wireless charging case for quick and easy recharging
- IPX5-rated sweat and water resistance
- Black and White color options
SOUNDFORM™ Play True Wireless Earbuds
The SOUNDFORM Play True Wireless Earbuds are the next generation of Belkin’s original SOUNDFORM True Wireless Earbuds offering more features such as EQ presets, improved battery life, and four different color options at an affordable price.
Key features:
- Dual Beamforming technology with 2 microphones in each earbud reduces environmental noise and provides audio clarity on calls
- 38 hours of battery life — up to 8 hours of playtime for the earbuds, plus 30 hours in the charging case
- 3 touch-controllable EQ presets for personalized sound
- 6mm dynamic drivers deliver clear, dependable sound quality
- Fast USB-C charging fully charges case and buds in just 1.5 hours
- IPX5-rated sweat and water resistance
- Intuitive touch controls in both earbuds allows users to tap to skip tracks, answer calls and more
- Midnight, Cloud, Petal and Ocean color options
SOUNDFORM™ Nano Wireless Earbuds for Kids
The SOUNDFORM Nano Wireless Earbuds for Kids deliver safe, high-quality sound up to 85dB volume limit, all-day comfort and extended battery life so children ages 7+ can safely listen to audio. The SOUNDFORM Nano Wireless Earbuds join the SOUNDFORM Mini Wireless Headphones in Belkin’s audio collection specifically designed for kids.
Key features:
- Safe Sound for Kids 85dB volume limit protects young, sensitive hearing from loud sounds
- 5 different ear tip size options, including extra-extra small, assure a comfortable fit and premium listening experience for smaller ears
- 24 hours of battery life – up to 5 hours of non-stop playtime, with an additional 19 hours of battery life in the charging case
- 6mm dynamic driver in each earbud makes favorite songs come alive
- IPX5 water resistance keeps earbuds safe as kids splash through puddles, dash through light rain, and play carefree
- Case and earbuds are fully charged in just 2 hours with the included micro-USB cable
- Blue, Pink and White color options
Pricing and Availability
- The SOUNDFORM Immerse are now available to order for $179.99 USD on Belkin.com.
- The SOUNDFORM Play are now available to order for $59.99 USD on Belkin.com
- The SOUNDFORM Nano are now available to order for $49.99 USD on Belkin.com.
Imagery can be found HERE .
About Belkin
Belkin is an accessories market leader delivering power, protection, productivity, connectivity and audio solutions for a broad range of consumer electronics and enterprise environments. Designed in Southern California and sold in more than 50 countries around the world, Belkin creates products that empower people through technology whether at home, at work or on a new adventure. In 2018, Belkin International merged with Foxconn Interconnect Technology to bolster its global influence and remains forever inspired by people and the planet we live on.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220607005084/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom